REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
Semantic ScholarReview

Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment

R. Salvador, C. Moutinho, Carla Sousa, A. Vinha, M. Carvalho, Carla Matos
Pharmaceuticals2025DOI: 10.3390/ph18030399

Citations

20

Subjects

Non-Human

Study Context

Review papers consolidate the current state of knowledge on a topic. While they don't present new experimental data, they offer valuable context and identify gaps in existing research.

Why This Matters

This research contributes to the growing body of evidence on semaglutide, glp-1. Understanding the mechanisms and clinical applications of these peptides is an active area of investigation.

Citation

R. Salvador, C. Moutinho, Carla Sousa et al.. (2025). Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment. Pharmaceuticals. https://doi.org/10.3390/ph18030399

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.